Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Sclerosis

At present, there is no approved medical use for cannabis in patients with neurological disorders. However, it is illegally used for spasticity and ataxia in patients with multiple sclerosis and spinal cord injury, and for the treatment of trigeminal nerve pain and, to a lesser extent, attention deficit hyperactivity disorder. Individuals with spinal cord injury have reported a reduction in spasticity after cannabis use. [Pg.229]


Cyasin, a component of the nut of the cycad tree, a native of tropical environs, produces an acute toxicity in addition to drastically increasing the incidence of Lou Gerhig s disease (amyotropic lateral sclerosis). Cyasin is carcinogenic (102). [Pg.481]

The class III cytokine receptor family includes two TNE receptors, the low affinity NGE receptor and 7-ceU surface recognition sites that appear to play a role in proliferation, apoptosis, and immunodeficiency. TNE-a (- 17, 000 protein) is produced by astrocytes and microglia and can induce fever, induce slow-wave sleep, reduce feeding, stimulate prostaglandin synthesis, stimulate corticotrophin-releasing factor and prolactin secretion, and reduce thyroid hormone secretion. TNE-a stimulates IL-1 release, is cytotoxic to oligodendrocytes, and reduces myelination this has been impHcated in multiple sclerosis and encephalomyelitis. Astrocyte TNE-a receptors mediate effects on IL-6 expression and augment astrocytic expression of MHC in response to other stimulants such as lEN-y. [Pg.539]

The immune system can malfunction either by attacking itself or the body (which happens in auto-immune diseases such as multiple sclerosis) or by being weakened itself in some way (such as what occurs as a result of the AIDS virus). [Pg.426]

Calpain Tissue specific calpains have been implicated in diabetes, cataracts, multiple sclerosis, and limb-girdle muscular dystrophy type 2A. More than 50 inhibitors of calpain have described which have a potential for therapeutic applications. [Pg.294]

Multiple sclerosis The 150-kDa calpain specific degradation product of a-spectrin increases 50% in human MS plaques.44 Degradation of the 68-kDa neurofilament protein is inhibited by a synthetic calpain inhibitor45... [Pg.313]

Neurological diseases Huntington s disease (A), amylotrophic lateral sclerosis (A,I), Parkinson s disease (A), traumatic brain injury (A,I), glaucoma (A)... [Pg.332]

Chemokines have been shown to be associated with a number of autoinflammatory diseases including multiple sclerosis, rheumatoid arthritis, atherosclerosis, dermatitis, and organ transplant rejection. Evidence, reviewed below, is mounting that chemokines may play a major role in the pathophysiology of these diseases and thus chemokine receptor antagonists could prove to be useful therapeutics in treating these and other proinflammatory diseases. [Pg.352]

Interferon beta-la (AVONEX , Rebif ), interferon beta-lb (Betaferon ), and interferon beta (Fiblaferon ) are applied in multiple sclerosis to reduce both frequency and severity of disease incidents and for the treatment of severe viral infections. In multiple sclerosis, DFN- 3 proteins modulate the destruction of myelin in the cause of the autoimmune reaction. [Pg.411]

Amyotropic lateral sclerosis (ALS) 3. AEA and 2-AG increase in the spinal cord of SOD1 transgenic mice, a model of ALS, to inhibit disease progress 3. CB2 receptor agonists or inhibitors of degradation... [Pg.467]

Multiple sclerosis (MS) 4. In rats with EAE, an animal model of multiple sclerosis, AEA and 2-AG levels are decreased in the striatum and midbrain. This might be associated with motor impairment 4. Inhibitors of degradation (both FAAH and cellular re-uptake)... [Pg.467]

Currently, baclofen is the only clinically used GAB Ab receptor agonist. It is used as a muscle relaxant for treatment of spasticity in spinal injury and multiple sclerosis. The cloning of GABAb receptors has renewed the interest in the search for more selective diugs and novel therapeutic indications. [Pg.519]

This experimental drug is a derivative of myriocin. After phosphorylation FTY720 modulates chemotactic responses and lymphocyte trafficking, leading to reversible lymphocyte sequestration in secondary lymphoid tissues. It is in clinical trials for the treatment of multiple sclerosis. [Pg.620]

In summary, the steadily increasing size of geriatric populations in developed countries and the resultant increases in age-related diseases of the brain have provided the impetus for intensive study of the processes underlying neurodegeneration. A better understanding of these processes will likely lead to better methods of treatment not only for progressive memory disorders such as Alzheimer disease, but also for motor disorders such as amyotrophic lateral sclerosis, and cerebrovascular disorders such as stroke. [Pg.827]

Sendtner M (1999) Neurotrophic factors and amyotrophic lateral sclerosis. Handbook of exp pharmacol. 134 81-117... [Pg.845]

CD C14 C14.010 Caspase-9 Potential drug target for amyotrophic lateral sclerosis... [Pg.878]

TSC1.2 Tuberous sclerosis complex hamartomas of the brain, heart, kidneys, skin, lungs, and eyes... [Pg.1216]


See other pages where Sclerosis is mentioned: [Pg.53]    [Pg.53]    [Pg.373]    [Pg.283]    [Pg.313]    [Pg.96]    [Pg.65]    [Pg.74]    [Pg.147]    [Pg.353]    [Pg.353]    [Pg.353]    [Pg.354]    [Pg.354]    [Pg.468]    [Pg.468]    [Pg.487]    [Pg.568]    [Pg.569]    [Pg.644]    [Pg.645]    [Pg.715]    [Pg.794]    [Pg.794]    [Pg.827]    [Pg.836]    [Pg.840]    [Pg.845]    [Pg.943]    [Pg.997]    [Pg.1105]    [Pg.1106]    [Pg.1215]    [Pg.1216]    [Pg.1250]   
See also in sourсe #XX -- [ Pg.348 ]

See also in sourсe #XX -- [ Pg.28 , Pg.75 ]

See also in sourсe #XX -- [ Pg.40 , Pg.90 ]

See also in sourсe #XX -- [ Pg.347 ]

See also in sourсe #XX -- [ Pg.7 , Pg.10 , Pg.25 ]

See also in sourсe #XX -- [ Pg.14 ]

See also in sourсe #XX -- [ Pg.169 , Pg.180 ]

See also in sourсe #XX -- [ Pg.31 , Pg.79 ]

See also in sourсe #XX -- [ Pg.179 , Pg.186 ]

See also in sourсe #XX -- [ Pg.28 , Pg.75 ]

See also in sourсe #XX -- [ Pg.81 , Pg.146 ]

See also in sourсe #XX -- [ Pg.124 ]

See also in sourсe #XX -- [ Pg.89 , Pg.90 ]

See also in sourсe #XX -- [ Pg.64 ]




SEARCH



Alemtuzumab multiple sclerosis

Amylotrophic lateral sclerosis

Amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis (ALS

Amyotrophic lateral sclerosis Axonal transport

Amyotrophic lateral sclerosis animal models

Amyotrophic lateral sclerosis antioxidants

Amyotrophic lateral sclerosis apoptosis

Amyotrophic lateral sclerosis clinical features

Amyotrophic lateral sclerosis creatine

Amyotrophic lateral sclerosis free radicals

Amyotrophic lateral sclerosis genetic factors

Amyotrophic lateral sclerosis genetics

Amyotrophic lateral sclerosis glutamate

Amyotrophic lateral sclerosis hereditary

Amyotrophic lateral sclerosis lipid peroxidation

Amyotrophic lateral sclerosis microglia

Amyotrophic lateral sclerosis minocycline

Amyotrophic lateral sclerosis motor neurons

Amyotrophic lateral sclerosis mutations

Amyotrophic lateral sclerosis overexpression

Amyotrophic lateral sclerosis pathogenesis

Amyotrophic lateral sclerosis pathology

Amyotrophic lateral sclerosis pathophysiology

Amyotrophic lateral sclerosis peroxynitrite

Amyotrophic lateral sclerosis riluzole

Amyotrophic lateral sclerosis sporadic

Amyotrophic lateral sclerosis superoxide dismutase

Amyotrophic lateral sclerosis treatment

Amyotrophic lateral sclerosis, neuronal degeneration

Amyotrophic lateral sclerosis, superoxide

Amyotrophic lateral sclerosis-Parkinsonian

Amyotrophic lateral sclerosis-Parkinsonism-dementia complex

Amyotrophic lateral sclerosis-like syndrome

Amyotropic Lateral Sclerosis

Animal models multiple sclerosis

Antigens multiple sclerosis

Autistic features in tuberous sclerosis

Autoantigen in multiple sclerosis

Autoimmune disease sclerosis

Autoimmune disease systemic sclerosis

Azathioprine multiple sclerosis

Biliary sclerosis

Cannabinoids multiple sclerosis

Cannabis multiple sclerosis

Central nervous system multiple sclerosis

Cerebrospinal fluid in multiple sclerosis

Cerebrospinal fluid multiple sclerosis

Chemokine in multiple sclerosis

Chemokine receptor in multiple sclerosis

Chemokines and their Receptors in Multiple Sclerosis

Connective tissue diseases systemic sclerosis

Coronary sclerosis

Cyclophosphamide multiple sclerosis

Demyelination multiple sclerosis-related

Demyelination, in multiple sclerosis

Differential diagnosis multiple sclerosis

Disease-modifying therapy, in multiple sclerosis

Drug abuse multiple sclerosis

Encapsulating peritoneal sclerosis

Environment multiple sclerosis

Epilepsy hippocampal sclerosis

Familial amyotrophic lateral sclerosis

Familial amyotrophic lateral sclerosis FALS)

Fatigue in multiple sclerosis

Features and Diagnosis of Multiple Sclerosis

Focal sclerosis

Genetic diseases amyotrophic lateral sclerosis

Hepatoportal sclerosis

High-resolution computed tomography systemic sclerosis

Hippocampal sclerosis

Immunoglobulins multiple sclerosis

Immunosuppressants multiple sclerosis

In multiple sclerosis

Infantile sclerosis

Interferon as multiple sclerosis treatment

Interferon in multiple sclerosis

Interferon with multiple sclerosis

Interstitial lung disease systemic sclerosis

Lateral sclerosis

Magnetic resonance imaging in multiple sclerosis

Magnetic resonance imaging multiple sclerosis

Methodology multiple sclerosis

Methotrexate multiple sclerosis

Methylprednisolone multiple sclerosis

Motor neuron disease and multiple sclerosis

Motor neuron diseases amyotrophic lateral sclerosis

Motor neurone disease sclerosis

Motor neurons Multiple sclerosis

Mouse model, multiple sclerosis

Multiple Sclerosis

Multiple Sclerosis (MS)

Multiple Sclerosis Functional Composite

Multiple sclerosis , chemokine expression

Multiple sclerosis Gilenya

Multiple sclerosis INDEX

Multiple sclerosis acute

Multiple sclerosis acute exacerbations

Multiple sclerosis acute relapses

Multiple sclerosis antimyelin antibodies

Multiple sclerosis apoptosis

Multiple sclerosis axonal damage

Multiple sclerosis benign

Multiple sclerosis bladder symptoms

Multiple sclerosis bowel symptoms

Multiple sclerosis case study

Multiple sclerosis central nervous system pathology

Multiple sclerosis cerebrospinal fluid protein

Multiple sclerosis clinical course

Multiple sclerosis clinical features

Multiple sclerosis clinical presentation

Multiple sclerosis copolymer

Multiple sclerosis corticosteroids

Multiple sclerosis cyclosporine

Multiple sclerosis cytokines

Multiple sclerosis demyelination

Multiple sclerosis depression

Multiple sclerosis diagnosis

Multiple sclerosis disease

Multiple sclerosis disease-modifying therapy

Multiple sclerosis drugs

Multiple sclerosis environmental factors

Multiple sclerosis epidemiology

Multiple sclerosis etiology

Multiple sclerosis evaluation

Multiple sclerosis experimental therapies

Multiple sclerosis failed clinical trials

Multiple sclerosis fatigue

Multiple sclerosis formulation

Multiple sclerosis genetic factors

Multiple sclerosis glatiramer acetate

Multiple sclerosis histamine

Multiple sclerosis imaging studies

Multiple sclerosis immune cells

Multiple sclerosis immunotherapy

Multiple sclerosis in terferon

Multiple sclerosis inflammation associated with

Multiple sclerosis interferon

Multiple sclerosis interferon beta therapies

Multiple sclerosis intravenous immunoglobulin

Multiple sclerosis lesions appearance

Multiple sclerosis magnetic resonance imaging studies

Multiple sclerosis markers

Multiple sclerosis microglia

Multiple sclerosis mimics

Multiple sclerosis mitoxantrone

Multiple sclerosis model

Multiple sclerosis model experimental allergic

Multiple sclerosis molecular- mimicry

Multiple sclerosis natalizumab

Multiple sclerosis neurological symptoms

Multiple sclerosis oligodendrocytes

Multiple sclerosis oral therapy

Multiple sclerosis outcome evaluation

Multiple sclerosis pathogenesis

Multiple sclerosis pathophysiology

Multiple sclerosis placebo effect

Multiple sclerosis prevalence

Multiple sclerosis progressive forms

Multiple sclerosis progressive relapsing

Multiple sclerosis relapses/exacerbations

Multiple sclerosis sensory symptoms

Multiple sclerosis side effects

Multiple sclerosis spasticity

Multiple sclerosis stem cell transplants

Multiple sclerosis symptomatic therapy

Multiple sclerosis therapeutic targeting

Multiple sclerosis treatment

Multiple sclerosis tremor

Multiple sclerosis trials

Multiple sclerosis tumor necrosis factor

Multiple sclerosis tumour necrosis factor

Multiple sclerosis viral models

Multiple sclerosis, differential

Multiple sclerosis, evening

Multiple sclerosis, evening primrose

Multiple sclerosis, nitric oxide role

Multiple sclerosis, precipitation

Myelin basic protein multiple sclerosis

Myelin multiple sclerosis

Myelin-associated glycoprotein multiple sclerosis

National Multiple Sclerosis Society

Neurochemical Aspects of Amyotropic Lateral Sclerosis

Neurodegenerative disease multiple sclerosis

Neurological diseases multiple sclerosis

Oligodendrocyte in multiple sclerosis

Optic nerve in multiple sclerosis

Parkinsons Disease and Amyotrophic Lateral Sclerosis

Plaques multiple sclerosis

Prednisone multiple sclerosis

Primary lateral sclerosis

Primary-progressive multiple sclerosis

Progressive systemic sclerosis

Proteases multiple sclerosis

Relapsing-remitting multiple sclerosis

Relapsing-remitting multiple sclerosis RRMS)

Sclerosis (MS)

Sclerosis and Other Demyelinating Diseases

Secondary-progressive multiple sclerosis

See Amyotrophic lateral sclerosis

Silica systemic sclerosis

Spasticity in multiple sclerosis

Spinal cord in amyotrophic lateral sclerosis

Stem Cell Therapy and Amyotrophic Lateral Sclerosis

Stem cells multiple sclerosis

Subject systemic sclerosis

Superoxide dismutase in amyotrophic lateral sclerosis

Systemic Sclerosis (Scleroderma)

Systemic sclerosis

Systemic sclerosis bronchoalveolar

Systemic sclerosis clinical features

Systemic sclerosis clinical presentation

Systemic sclerosis diagnosis

Systemic sclerosis etiology

Systemic sclerosis genes

Systemic sclerosis genetics

Systemic sclerosis imaging

Systemic sclerosis interstitial pneumonia

Systemic sclerosis pathogenesis

Systemic sclerosis pathology

Systemic sclerosis prevalence

Systemic sclerosis treatment

Systemic sclerosis treatment response

Therapeutic drugs multiple sclerosis

Treatment of Multiple Sclerosis

Trichloroethylene systemic sclerosis

Tuberous sclerosis

Tuberous sclerosis complex

Vigabatrin tuberous sclerosis

Vitamin D (cont multiple sclerosis

© 2024 chempedia.info